Towards Healthcare
Cell and Gene Supply Chain Solutions Market to Rise at 15.54% CAGR till 2034

Cell and Gene Supply Chain Solutions Market Expands with AI in 2025

Based on market forecasts, the global cell and gene supply chain solutions market, projected at USD 3.54 billion in 2024, is expected to reach USD 14.95 billion by 2034, growing at a CAGR of 15.54% over the forecast period. The cell and gene supply chain solutions market is growing due to the rising need for personalized therapies. North America’s dominance is due to advancements in FDA approvals related to biologics.

Content

  • Insight Code: 6109
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Rohan Patil is a seasoned market research professional with over 5 years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

He began his journey with Precedence Research, where he played a pivotal role in developing high-impact healthcare market reports. Today, Rohan leads research initiatives at Towards Healthcare, while also contributing to Statifacts, where he supports cross-industry analysis and data-driven storytelling.

Rohan’s core strengths lie in trend analysis and emerging technologies, regulatory monitoring and thought leadership through high-quality report writing. He excels at identifying future-ready opportunities and translating complex data into strategic recommendations. His work spans pharmaceuticals, biotechnology, medical devices, and digital health, assessing everything from market potential and competitive positioning to customer needs and regulatory shifts.

A trusted advisor and a relentless innovator, Rohan continues to push the boundaries of traditional market research, merging scientific rigor with commercial insight to stay ahead in a fast-evolving healthcare landscape.

Talk to us
FAQ's

The cell and gene supply chain solutions market is worth USD 4.09 billion in 2025, and by 2034, it is forecasted to hit USD 14.95 billion, registering a CAGR of 15.54% over the decade.

North America is currently leading the cell and gene supply chain solutions market share 40% due to rising demand for therapeutics in rare diseases.

Some key players include Thermo Fisher Scientific, Lonza Group, Cryport Inc., Marken, World Courier, etc.

Key trends include rising clinical trial approvals by the FDA and the need for developing advanced therapeutics for cancer.

Gene therapy is customised for every patient. The lengthy course of therapy may take up to a year to finish. Throughout the procedure, patients will spend varying amounts of time in the hospital.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions